CD79A and neoplasm: In combination with the abundance of EpCAM on PDAC patient material and the observation that tumor cells can be killed ex vivo by neutrophils upon IgA-EpCAM treatment in combination with CD47 blockade, we provide a basis for further exploration of IgA-EpCAM antibodies for the treatment of this therapy resistant disease.